SEC Form 4/A · accession 0001859453-26-000011
Vera Therapeutics, Inc. · VERA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Marshall Fordyce
Officer — PRESIDENT AND CEO · Director
Period of report
May 12, 2026
Accepted (ET)
Aug 12, 2026 · 6:39 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001831828
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | May 12, 2026 | M | 18,500 | $2.8968 | A | 253,744 | D | |
| Class A Common StockF3,F1 | May 12, 2026 | S | 14,219 | $36.6396 | D | 239,525 | D | |
| Class A Common StockF4,F1 | May 12, 2026 | S | 4,281 | $37.0868 | D | 235,244 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $2.8968 | May 12, 2026 | M | 18,500 | D | — | Dec 15, 2030 | Class A Common Stock | 18,500 | 590,551 | D |
Explanation of responses
- F1This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
- F2The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F51/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.